Aerosolisable Formulation Using TRP Modulators for Flavor Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing e-cigarettes face challenges in providing an aerosol that mimics the complex flavor and sensation of tobacco smoke, with flavor degradation leading to diminished user experience and the need for excess flavor additives, while also failing to reduce toxicant formation.

Innovation Solution

An aerosolisable formulation containing active agents, carriers like water and propylene glycol, and modulators such as TRPA1 agonists, TRPM8 agonists, TRPV1 agonists, TRPV3 agonists, TRPA1 antagonists, or TRPA1 inhibitors to enhance flavor and reduce harshness.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If flavor components are heated to generate aerosol, then aerosol is produced for inhalation, but flavor degradation occurs resulting in diminished flavor experience

Engineering Contradiction:
Improveaerosol generationVSAvoidflavor stability
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent introduces modulators (TRPA1 agonists, TRPM8 agonists, TRPV1 agonists, TRPV3 agonists, TRPA1 antagonists, or TRPA1 inhibitors) that interact with thermal and chemical sensory receptors to modify the perception of heat and flavor degradation. These modulators change the sensory parameters experienced by the user, allowing the aerosol to be generated while masking or reducing the negative effects of flavor component degradation.

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If excess flavor is added to compensate for degradation, then flavor intensity is maintained, but cost increases and flavor balance is disrupted

Engineering Contradiction:
Improveflavor intensityVSAvoidformulation cost and complexity
Core Design Contradiction:
Quantity of substanceVSEase of manufacture

Solution Approach 1:

The modulators act as intermediary substances that mediate between the degraded flavor components and the user's sensory receptors. Instead of adding more flavor to compensate for degradation, the modulators intervene in the sensory transduction process, allowing standard flavor concentrations to maintain their perceived intensity while reducing the need for excessive flavor additives.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Quantity of substance

If e-cigarette generates aerosol with intense flavor, then user experience is enhanced, but harshness and irritation increase

Engineering Contradiction:
Improveflavor intensityVSAvoidharshness and irritation
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The modulators are incorporated into the formulation to preemptively counteract the harshness and irritation that would otherwise result from intense flavor delivery. By pre-loading the aerosol with substances that modulate sensory receptor response, the system prepares the user's sensory system to perceive the aerosol more favorably before the actual inhalation and sensory stimulation occurs.

Inventive Principle:
Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation improves the sensorial properties of the aerosol, reducing harshness and enhancing flavor intensity, while potentially reducing toxicant formation.

Implementation Method 1

a heater is activated to vaporise a small amount of liquid

Methodology Applied
Scientific EffectVaporization: Evaporation

Data Source

PatentUS20250380732A1Aerosolisable formulation
Publication Date: 2025.12.18 NICOVENTURES TRADING LTD
  • US20250380732A1 patent drawing
  • US20250380732A1 patent drawing
  • US20250380732A1 patent drawing

AI summary

There is provided an aerosolisable formulation comprising (a) at least one active agent; (b) aerosol former material; (c) a modulator selected from a TRPA1 agonist, a TRPMS agonist, a TRPV1 agonist, a TRPV3 agonist, a TRPA1 antagonist, a TRPA1 inhibitor and combinations thereof, and (d) one or more binders.